BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
about
Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsThe impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic reviewMelanoma: new insights and new therapiesOptimal management of metastatic melanoma: current strategies and future directionsProgression of cutaneous melanoma: implications for treatmentTumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab TherapyClinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertensionA phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1)Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to dateIncreased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis.Therapy for metastatic melanoma: the past, present, and future.A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.A review of novel therapies for melanoma.Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Biomarkers for anti-angiogenic therapy in cancer.A pilot study of bevacizumab and interferon-α2b in ocular melanoma.Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomasA phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.Targeting angiogenesis in melanoma: prospects for the futureSorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studiesAflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal originThe combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers.Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study.Adjuvant treatment of melanomaBevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma.The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma.Identification of a Novel Pathogenic Germline KDR Variant in Melanoma.A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma.Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).Metastatic melanoma - a review of current and future drugsToward the development of a novel non-RGD cyclic peptide drug conjugate for treatment of human metastatic melanomaBRAF and beyond: Tailoring strategies for the individual melanoma patient
P2860
Q26770492-A072BE32-E088-4480-B780-3FD9C4D191A3Q26786618-1FFC4869-D898-4E0B-AE52-321558F9DDC3Q26824086-FB5F03A2-2CA9-4294-B8CE-17CF76AE9AFEQ26853127-AD9B8FA7-BD15-4CFC-BDF2-75098A955FA9Q26997338-8AA8B9F1-7C5D-43FF-8D7E-DB0DF8107BECQ27001734-4A8B1B98-12BD-4C88-8F95-114595829DB6Q28550733-FD2C41E3-FCA6-426B-975E-E22D188121AAQ28728389-4BA70F47-F98D-449E-835B-206676B46CEAQ33394828-AF279B4C-92DE-4970-88F7-44AED13C7792Q33404877-8295880A-A43D-4044-967E-6DA03322AD59Q33415219-D3B462CE-7A30-4CD7-9B9E-76ACD5CA391CQ33667485-96D2BA22-06F4-4999-A131-A8023C019410Q33770680-8E923B4F-7CEB-4691-9100-41B676B7FE91Q33871014-6524ADEA-FDCE-4E7E-A272-B5BEE7FBE5D3Q33887664-9F068634-BD3A-4DFA-914C-912CC4737D54Q33904867-E8387206-3153-44F2-AE6B-3ACEFA900FEDQ34183225-893CB55E-592B-4614-8131-3C1DA9D9A3BDQ34241208-DEA8372D-20F4-46B6-BBBF-23EE67F152CCQ34424764-540E24EA-2E0E-4B58-A129-1997F34D7A04Q34642874-B4A1ECDE-711C-4598-AD07-13349DCF0FC6Q34695003-BE6F57C0-0457-48B7-AA9B-94E34A26FBA6Q34961777-A48B6B51-1C41-442D-97C8-3A1C88539AE5Q35018167-184DC014-E626-41B2-BF17-1EC475110D1DQ35050558-D3A33553-9973-469A-AD30-AA7EEB4DE407Q35076316-AF7D8BE9-FAEB-423D-B9D4-766AED29E5EBQ35212678-2DA75067-B0A9-4DE3-B6B8-48AAD8F423F2Q35377689-2CCD4F7B-CF6A-4B24-B284-E5CCE646A48DQ35475284-E2F83206-E107-41CE-8CFB-441727932420Q35691033-54085143-BBA3-46FC-8D29-CE76FA5F07FFQ35915719-3F0946C5-6FF0-4740-9FAB-03C30155C98DQ36014062-C7B7C695-F035-437A-8C5A-8626BFF9D0FFQ36656595-6993D855-EAF2-4049-A563-BAF3DF232730Q36744566-9EB875DB-6699-4E19-A8FD-A59F4FABC377Q36887861-883176B5-31F2-46E3-B9C7-BAC62E3F3C74Q36902033-7EDCB88B-4ABE-4072-8663-772EC3C09624Q36984477-B31FCCC9-CA12-4F82-8E50-24F300EB846AQ37329315-C7EAB2C4-9A41-458A-87C0-9BC11A14AA06Q37450733-D1587744-C8B6-4F00-B72A-66C33D2CEF1EQ37702351-06B77135-A9EB-408E-92F9-519E709C4BFAQ37702515-549B1080-ED6F-43C8-A5DF-47A381F72AF8
P2860
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
BEAM: a randomized phase II st ...... y untreated advanced melanoma.
@ast
BEAM: a randomized phase II st ...... y untreated advanced melanoma.
@en
type
label
BEAM: a randomized phase II st ...... y untreated advanced melanoma.
@ast
BEAM: a randomized phase II st ...... y untreated advanced melanoma.
@en
prefLabel
BEAM: a randomized phase II st ...... y untreated advanced melanoma.
@ast
BEAM: a randomized phase II st ...... y untreated advanced melanoma.
@en
P2093
P2860
P356
P1476
BEAM: a randomized phase II st ...... ly untreated advanced melanoma
@en
P2093
Amy C Peterson
David F McDermott
Gerald P Linette
Hoa Nguyen
Jeffrey A Sosman
Jeffrey S Weber
John P Fruehauf
Kevin B Kim
Peter Cheverton
Steven J O'Day
P2860
P356
10.1200/JCO.2011.34.6270
P407
P577
2011-11-28T00:00:00Z